Biovest to expand phase 3 trial of BiovaxID in Ukraine and Russia

New York, June 6 - Biovest International, Inc. said it has filed for regulatory approval to open up to 30 new clinical sites for its pivotal phase 3 trial of BiovaxID for the treatment of follicular non-Hodgkin's lymphoma.

The filings have been submitted by the contract research organizations which will manage the trials for Biovest in Ukraine and Russia and will be responsible for monitoring patient recruitment and overseeing all aspects of the studies.

The opening of these sites is expected to dramatically increase the number of patients being treated with BiovaxID during the next 12 to 18 months, the company said.

Enrollment is expected to be completed by late 2007.

Biovest is a Worcester, Mass., developer of immunotherapies for life-threatening cancers of the blood system.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.